Why Johnson & Johnson (NYSE:JNJ) Could Be Your Next Investment

Johnson & Johnson (NYSE:JNJ) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In the case of JNJ, it is a notable dividend payer with a great history of delivering benchmark-beating performance. Below, I've touched on some key aspects you should know on a high level. If you're interested in understanding beyond my broad commentary, take a look at the report on Johnson & Johnson here.

Advertisement

Solid track record established dividend payer

In the past couple of years, JNJ has ramped up its bottom line by over 100%, with its latest earnings level surpassing its average level over the last five years. This illustrates a strong track record, leading to a satisfying return on equity of 28%, which is an optimistic signal for the future.

NYSE:JNJ Income Statement, July 29th 2019
NYSE:JNJ Income Statement, July 29th 2019

For those seeking income streams from their portfolio, JNJ is a robust dividend payer as well. Over the past decade, the company has consistently increased its dividend payout, reaching a yield of 2.9%.

NYSE:JNJ Historical Dividend Yield, July 29th 2019
NYSE:JNJ Historical Dividend Yield, July 29th 2019

Next Steps:

For Johnson & Johnson, I've compiled three relevant aspects you should further research:

  1. Future Outlook: What are well-informed industry analysts predicting for JNJ’s future growth? Take a look at our free research report of analyst consensus for JNJ’s outlook.
  2. Financial Health: Are JNJ’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of JNJ? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NYSE:JNJ

Johnson & Johnson

Engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.

Established dividend payer and fair value.

Advertisement

Weekly Picks

LO
Lou_Basenese
CUE logo
Lou_Basenese on Cue Biopharma ·

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Fair Value:US$7056.5% undervalued
23 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$317.225.0% undervalued
11 users have followed this narrative
6 users have commented on this narrative
6 users have liked this narrative
NI
niteco
AVGO logo
niteco on Broadcom ·

A Capital Allocation Favorite with Structural Importance

Fair Value:US$651.0539.8% undervalued
6 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
TO
Tokyo
OKTA logo
Tokyo on Okta ·

Good foundation, but now it's all about the next steps

Fair Value:US$15120.6% undervalued
82 users have followed this narrative
7 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$317.225.0% undervalued
11 users have followed this narrative
6 users have commented on this narrative
0 users have liked this narrative
VA
Valtersa
ZVRA logo
Valtersa on Zevra Therapeutics ·

Discounted Exit Multiple Approach (DEM)

Fair Value:US$15.411.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
SU
INTC logo
Suen on Intel ·

Intel Story

Fair Value:US$500.9378.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7447.8% undervalued
58 users have followed this narrative
0 users have commented on this narrative
15 users have liked this narrative
CL
Clive_Thompson
TTWO logo
Clive_Thompson on Take-Two Interactive Software ·

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Fair Value:US$276.9723.4% undervalued
57 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
NI
niteco
HON logo
niteco on Honeywell International ·

Honeywell - The Demand-Side of the AI Infrastructure

Fair Value:US$320.1932.6% undervalued
48 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative